The survival benefit of percutaneous LVAD therapy varies significantly according to the patient’s shock phenotype and underlying clinical risk profile. A nationwide analysis published in the European Heart Journal assessed outcomes of percutaneous left ventricular assist device (LVAD) use among patients with acute myocardial infarction–related cardiogenic shock (AMI-CS) in Japan, highlighting striking heterogeneity across clinical subgroups.

Using data from 3,975 patients enrolled in the J-PVAD registry (2020–2023), investigators compared DanGer shock–eligible patients with broader real-world cohorts. Only 35.6% fulfilled the DanGer shock trial criteria, showing a 30-day mortality of 37.6%. Non-eligible ST-elevation myocardial infarction (STEMI) cases had lower mortality (27.6%), though outcomes worsened with advanced age, renal dysfunction, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) support, ventricular arrhythmia, or sepsis. Mortality was highest in out-of-hospital cardiac arrest (51.3%) and mechanical complications (39.8%).

These findings confirm that while percutaneous LVAD support remains a vital component of cardiogenic shock management, real-world outcomes vary widely. Tailored risk assessment and judicious patient selection are critical to optimizing survival in infarction-related shock.